ARS Pharmaceuticals, Inc. SPRY US — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s us — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s US — revenue?
- ARS Pharmaceuticals, Inc. (SPRY) reported US — revenue of $17.45M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s US — revenue changed year-over-year?
- ARS Pharmaceuticals, Inc.'s US — revenue increased by 124.8% year-over-year, from $7.76M to $17.45M.
- What does US — revenue mean?
- This metric represents the total gross revenue generated from the sale of pharmaceutical products or services within the United States market, net of any assessed taxes. It serves as a primary indicator of market penetration and commercial adoption for the company's therapeutic offerings in this specific geographic region. Tracking this figure allows investors to evaluate the growth trajectory and commercial success of the company's product portfolio within the domestic healthcare landscape.